Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the prospects and plans for J&J’s pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda; and Moderna’s co-founder shares tips on innovation.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 12 November 2021, including: the prospects and plans for Johnson & Johnson’s pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda Pharmaceutical Co. Ltd.; and Moderna, Inc.’s co-founder shares tips on innovation.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "No Way To Go But Grow: J&J Outlines Plans To Become A $60bn Pharma In 2025" - Scrip, 18 Nov, 2021.)
(Also see "Pharma Will Need To Embrace More Inward-Looking China" - Scrip, 24 Nov, 2021.)
(Also see "Takeda's Livtencity Approved For Refractory CMV Infection In Transplant Patients" - Scrip, 25 Nov, 2021.)
(Also see "Moderna Co-Founder Robert Langer’s Tips For Innovation" - Scrip, 22 Nov, 2021.)